Liquid biopsies in primary and secondary bone cancers

Abstract

Liquid biopsies are a powerful tool to non-invasively analyze tumor phenotype and progression as well as drug resistance. In the bone oncology field, liquid biopsies would be particularly important to develop, since standard biopsies can be very painful, dangerous (e.g., when found in proximity to the spinal cord), and hard to collect. In this review, we explore the recent advances in liquid biopsies in both primary (osteosarcoma and Ewing sarcoma) and secondary bone cancers (breast, prostate, and lung cancer-induced bone metastases), presenting their current role and highlighting their unexpressed potential, as well as the barriers limiting their possible adoption, including costs, scalability, reproducibility, and isolation methods. We discuss the use of circulating tumor cells, cell-free circulating tumor DNA, and extracellular vesicles for the purpose of improving diagnosis, prognosis, evaluation of therapy resistance, and driving therapy decisions in both primary and secondary bone malignancies.

Keywords

Liquid biopsy / bone metastasis / osteosarcoma / Ewing sarcoma / extracellular vesicles / minimal residual disease / drug resistance

References

[1] Robey P. Noncollagenous bone matrix proteins.Princ Bone Biol2008;1:335-49

[2] Florencio-Silva R,Sasso-Cerri E,Cerri PS.Biology of bone tissue: structure, function, and factors that influence bone cells.Biomed Res Int2015;2015:421746 PMCID:PMC4515490

[3] Siddiqui JA.Physiological bone remodeling: systemic regulation and growth factor involvement.Physiology (Bethesda)2016;31:233-45 PMCID:PMC6734079

[4] Raisz LG.Physiology and pathophysiology of bone remodeling.Clin Chem1999;45:1353-8

[5] Kenkre JS.The bone remodelling cycle.Ann Clin Biochem2018;55:308-27

[6] Capulli M,Rucci N.Osteoblast and osteocyte: games without frontiers.Arch Biochem Biophys2014;561:3-12

[7] Wang L,Zhang L,Zou W.Mechanical regulation of bone remodeling.Bone Res2022;10:16 PMCID:PMC8857305

[8] Cullinane DM.The role of osteocytes in bone regulation: mineral homeostasis versus mechanoreception.J Musculoskelet Neuronal Interact2002;2:242-4

[9] Qin L,Cao H.Molecular mechanosensors in osteocytes.Bone Res2020;8:23 PMCID:PMC7280204

[10] Mirabello L,Savage SA.International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons.Int J Cancer2009;125:229-34

[11] Durfee RA,Luu HH.Review of osteosarcoma and current management.Rheumatol Ther2016;3:221-43 PMCID:PMC5127970

[12] Siegel RL,Fuchs HE.Cancer statistics, 2022.CA A Cancer J Clinicians2022;72:7-33

[13] Kundu ZS.Classification, imaging, biopsy and staging of osteosarcoma.Indian J Orthop2014;48:238-46 PMCID:PMC4052020

[14] Misaghi A,Awad M.Osteosarcoma: a comprehensive review.SICOT J2018;4:12 PMCID:PMC5890448

[15] Li S,Wang H,Hua Y.Research progress on the multidrug resistance mechanisms of osteosarcoma chemotherapy and reversal.Tumour Biol2015;36:1329-38

[16] Fanelli M,Patrizio MP.Cisplatin resistance in osteosarcoma: in vitro validation of candidate DNA repair-related therapeutic targets and drugs for tailored treatments.Front Oncol2020;10:331 PMCID:PMC7077033

[17] Tu J,Gingold J,Shen J.The histogenesis of ewing sarcoma.Cancer Rep Rev2017;1:10.15761/CRR.1000111 PMCID:PMC5472389

[18] Esiashvili N,Marcus RB Jr.Changes in incidence and survival of ewing sarcoma patients over the past 3 decades: surveillance epidemiology and end results data.J Pediatr Hematol Oncol2008;30:425-30

[19] May WA,Keshelava N.Characterization and drug resistance patterns of Ewing’s sarcoma family tumor cell lines.PLoS One2013;8:e80060 PMCID:PMC3846563

[20] Duchman KR,Miller BJ.Prognostic factors for survival in patients with Ewing’s sarcoma using the surveillance, epidemiology, and end results (SEER) program database.Cancer Epidemiol2015;39:189-95

[21] Granowetter L,Devidas M.Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a children’s oncology group study.J Clin Oncol2009;27:2536-41 PMCID:PMC2684856

[22] Bailey KM.Prospective investigation of drug resistance: an approach to understanding and optimizing the clinical benefit of targeted agents in Ewing sarcoma.Oncotarget2018;9:37270-1 PMCID:PMC6324671

[23] Macedo F,Pinho F.Bone metastases: an overview.Oncol Rev2017;11:321 PMCID:PMC5444408

[24] Quiroz-Munoz M,Arumugam D,Kirschenbaum A.Mechanisms of osteoblastic bone metastasis in prostate cancer: role of prostatic acid phosphatase.J Endocr Soc2019;3:655-64 PMCID:PMC6397422

[25] Turpin A,Vieillard MH.Bone metastasis: current state of play.Transl Oncol2020;13:308-20 PMCID:PMC6931192

[26] Roodman GD.Mechanisms of bone metastasis.N Engl J Med2004;350:1655-64

[27] Joeckel E,Prawitt D.High calcium concentration in bones promotes bone metastasis in renal cell carcinomas expressing calcium-sensing receptor.Mol Cancer2014;13:42 PMCID:PMC3945739

[28] Ardura JA,Gutiérrez-Rojas I.Role of calcium signaling in prostate cancer progression: effects on cancer hallmarks and bone metastatic mechanisms.Cancers (Basel)2020;12:1071 PMCID:PMC7281772

[29] Owyong M,van den Bijgaart RJ.MMP9 modulates the metastatic cascade and immune landscape for breast cancer anti-metastatic therapy.Life Sci Alliance2019;2:e201800226 PMCID:PMC6856766

[30] Deryugina EI.Matrix metalloproteinases and tumor metastasis.Cancer Metastasis Rev2006;25:9-34

[31] Rucci N.Osteomimicry: how the seed grows in the soil.Calcif Tissue Int2018;102:131-40

[32] Capulli M,Valbret Z.Notch2 pathway mediates breast cancer cellular dormancy and mobilisation in bone and contributes to haematopoietic stem cell mimicry.Br J Cancer2019;121:157-71 PMCID:PMC6738045

[33] Pape F, Vargas G, Clézardin P. The role of osteoclasts in breast cancer bone metastasis.J Bone Oncol2016;5:93-5 PMCID:PMC5063222

[34] Ponzetti M.Switching homes: how cancer moves to bone.Int J Mol Sci2020;21:4124 PMCID:PMC7313057

[35] Guise TA,Taylor SD.Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis.J Clin Invest1996;98:1544-9 PMCID:PMC507586

[36] Kang J,Bonollo F.Tumor microenvironment mechanisms and bone metastatic disease progression of prostate cancer.Cancer Lett2022;530:156-69

[37] Yin JJ,Käkönen SM.A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases.Proc Natl Acad Sci USA2003;100:10954-9 PMCID:PMC196909

[38] Eslami-s Z,Alix-panabières C.The metastatic cascade as the basis for liquid biopsy development.Front Oncol2020;10:1055 PMCID:PMC7396546

[39] Palmirotta R,Cafforio P.Liquid biopsy of cancer: a multimodal diagnostic tool in clinical oncology.Ther Adv Med Oncol2018;10:1758835918794630 PMCID:PMC6116068

[40] Li X,Hornicek FJ,Duan Z.Application of liquid biopsy in bone and soft tissue sarcomas: Present and future.Cancer Lett2018;439:66-77

[41] Joerger M.Diagnostic and prognostic use of bone turnover markers.Recent Results Cancer Res2012;192:197-223

[42] Singer FR.Using biochemical markers of bone turnover in clinical practice.Cleve Clin J Med2008;75:739-50

[43] Huang Q.Biochemical-markers for the diagnosis of bone metastasis: a clinical review.Cancer Epidemiol2012;36:94-8

[44] Kushlinskii NE,Solov’ev YN.Vascular endothelium growth factor and angiogenin in the serum of patients with osteosarcoma and Ewing’s tumor.Bull Exp Biol Med2000;130:691-3

[45] Krizkova S,Majzlik P.Serum metallothionein in newly diagnosed patients with childhood solid tumours.Acta Biochim Pol2010;57:561-6

[46] Markiewicz K,Kozar A.Evaluation of selected cytokines in children and adolescents with osteosarcoma at diagnosis - preliminary report.Med Wieku Rozwoj2011;15,25-31

[47] Liu T,Zhang Y.Self-seeding circulating tumor cells promote the proliferation and metastasis of human osteosarcoma by upregulating interleukin-8.Cell Death Dis2019;10:575 PMCID:PMC6668432

[48] Perakis S.Emerging concepts in liquid biopsies.BMC Med2017;15:75 PMCID:PMC5382440

[49] Wit S, van Dalum G, Terstappen LW. Detection of circulating tumor cells.Scientifica (Cairo)2014;2014:819362 PMCID:PMC4124199

[50] Yang C,Jin WL.Circulating tumor cells in precision oncology: clinical applications in liquid biopsy and 3D organoid model.Cancer Cell Int2019;19:341 PMCID:PMC6918690

[51] Mauri G,Amatu A.The evolutionary landscape of treatment for BRAF^V600E mutant metastatic colorectal cancer.Cancers2021;13:137 PMCID:PMC7795863

[52] Ascierto PA,Grob JJ.The role of BRAF V600 mutation in melanoma.J Transl Med2012;10:85 PMCID:PMC3391993

[53] Pellegrini C,Cipolloni G.Heterogeneity of BRAF, NRAS, and TERT promoter mutational status in multiple melanomas and association with MC1R genotype: findings from molecular and immunohistochemical analysis.J Mol Diagn2018;20:110-22

[54] Rashid FA,Khan MS,Bhat MH.Variations in MAPkinase gladiators and risk of differentiated thyroid carcinoma.Mol Clin Oncol2022;16:45 PMCID:PMC8739702

[55] Crowley E,Loupakis F.Liquid biopsy: monitoring cancer-genetics in the blood.Nat Rev Clin Oncol2013;10:472-84

[56] Colombo M,Théry C.Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles.Annu Rev Cell Dev Biol2014;30:255-89

[57] Doyle LM.Overview of extracellular vesicles, their origin, composition, purpose, and methods for exosome isolation and analysis.Cells2019;8:727 PMCID:PMC6678302

[58] Stevic I,Ricklefs FL.Monitoring therapy efficiency in cancer through extracellular vesicles.Cells2020;9:130 PMCID:PMC7017260

[59] Green TM,Barsky SH,Lorico A.Breast cancer-derived extracellular vesicles: characterization and contribution to the metastatic phenotype.Biomed Res Int2015;2015:634865 PMCID:PMC4639645

[60] Taverna S,D’Ascenzo S,Dolo V.Breast cancer derived extracellular vesicles in bone metastasis induction and their clinical implications as biomarkers.Int J Mol Sci2020;21:3573 PMCID:PMC7278927

[61] Loftus A,George C.Extracellular vesicles from osteotropic breast cancer cells affect bone resident cells.J Bone Miner Res2020;35:396-412

[62] Cappariello A.Tumour-derived extracellular vesicles (EVs): a dangerous “Message in A Bottle” for bone.Int J Mol Sci2019;20:4805 PMCID:PMC6802008

[63] Valencia K,Bovy N.miRNA cargo within exosome-like vesicle transfer influences metastatic bone colonization.Mol Oncol2014;8:689-703 PMCID:PMC5528646

[64] Ucci A,Ponzetti M.Anti-osteoblastogenic, pro-inflammatory and pro-angiogenic effect of extracellular vesicles isolated from the human osteosarcoma cell line MNNG/HOS.Bone2021;153:116130

[65] Lan M,Cao ZY,Lin Q.Extracellular vesicles-mediated signaling in the osteosarcoma microenvironment: Roles and potential therapeutic targets.J Bone Oncol2018;12:101-4 PMCID:PMC6111053

[66] Perut F,Baldini N.The emerging roles of extracellular vesicles in osteosarcoma.Front Oncol2019;9:1342 PMCID:PMC6901498

[67] Gassmann H,Evdokimova V.Ewing sarcoma-derived extracellular vesicles impair dendritic cell maturation and function.Cells2021;10:2081 PMCID:PMC8391167

[68] Pachva MC,Jia A,Sorensen PH.Extracellular vesicles in reprogramming of the ewing sarcoma tumor microenvironment.Front Cell Dev Biol2021;9:726205 PMCID:PMC8484747

[69] Bebelman MP,Pegtel DM.The forces driving cancer extracellular vesicle secretion.Neoplasia2021;23:149-57

[70] Ludwig N,Reichert TE.Challenges in exosome isolation and analysis in health and disease.Int J Mol Sci2019;20:4684 PMCID:PMC6801453

[71] Kim KM,Mustapic M,Gorospe M.RNA in extracellular vesicles.Wiley Interdiscip Rev RNA2017;8:e1413 PMCID:PMC5474163

[72] Siravegna G,Siena S.Integrating liquid biopsies into the management of cancer.Nat Rev Clin Oncol2017;14:531-48

[73] Incorvaia L,Perez A.Liquid biopsy in breast cancer. In Liquid biopsy in cancer patients Current Clinical Pathology; Cham: Humana Press; 2017. p. 77-84.

[74] Olsson E,George A.Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease.EMBO Mol Med2015;7:1034-47 PMCID:PMC4551342

[75] Garcia-Murillas I,Weigelt B.Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer.Sci Transl Med2015;7:302ra133

[76] Beaver JA,Balukrishna S.Detection of cancer DNA in plasma of patients with early-stage breast cancer.Clin Cancer Res2014;20:2643-50 PMCID:PMC4024333

[77] Pécuchet N,Didelot A.Base-position error rate analysis of next-generation sequencing applied to circulating tumor DNA in non-small cell lung cancer: a prospective study.PLoS Med2016;13:e1002199 PMCID:PMC5189949

[78] Jia J,Zhuang Z.Circulating tumor DNA as prognostic markers for late stage NSCLC with bone metastasis.Int J Biol Markers2018;33:222-30

[79] Vandekerkhove G,Annala M.Circulating tumor DNA abundance and potential utility in de novo metastatic prostate cancer.Eur Urol2019;75:667-75

[80] Bidard F,Fehm T.Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data.Lancet Oncol2014;15:406-14

[81] Moussavi-Harami SF,Beebe DJ.Circulating tumor cells in metastatic breast cancer: a prognostic and predictive marker.J Patient Cent Res Rev2014;1:85-92 PMCID:PMC4405902

[82] De Giorgi U,Rohren E.Circulating tumor cells and bone metastases as detected by FDG-PET/CT in patients with metastatic breast cancer.Ann Oncol2010;21:33-9

[83] Baccelli I,Riethdorf S.Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay.Nat Biotechnol2013;31:539-44

[84] Cheng M,Yang HS.Circulating tumor cells are associated with bone metastasis of lung cancer.Asian Pac J Cancer Prev2014;15:6369-74

[85] Krebs MG,Priest L.Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer.J Clin Oncol2011;29:1556-63

[86] Shaffer DR,Danila DC.Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer.Clin Cancer Res2007;13:2023-9

[87] de Bono JS,Montgomery RB.Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer.Clin Cancer Res2008;14:6302-9

[88] Helo P,Danila DC.Circulating prostate tumor cells detected by reverse transcription-PCR in men with localized or castration-refractory prostate cancer: concordance with CellSearch assay and association with bone metastases and with survival.Clin Chem2009;55:765-73 PMCID:PMC2782624

[89] Bortolini Silveira A,Tanguy ML.Multimodal liquid biopsy for early monitoring and outcome prediction of chemotherapy in metastatic breast cancer.NPJ Breast Cancer2021;7:115 PMCID:PMC8429692

[90] Kodahl AR,Pallisgaard N.Correlation between circulating cell-free PIK3CA tumor DNA levels and treatment response in patients with PIK3CA-mutated metastatic breast cancer.Mol Oncol2018;12:925-35 PMCID:PMC5983134

[91] Dawson SJ,Murtaza M.Analysis of circulating tumor DNA to monitor metastatic breast cancer.N Engl J Med2013;368:1199-209

[92] Wang P,Gyanchandani R.Sensitive detection of mono- and polyclonal ESR1 mutations in primary tumors, metastatic lesions, and cell-free DNA of breast cancer patients.Clin Cancer Res2016;22:1130-7 PMCID:PMC4775406

[93] Rossi G,Rademaker AW.Cell-free DNA and circulating tumor cells: comprehensive liquid biopsy analysis in advanced breast cancer.Clin Cancer Res2018;24:560-8

[94] Bhadresha KP,Jain NK.A predictive biomarker panel for bone metastases: liquid biopsy approach.J Bone Oncol2021;29:100374 PMCID:PMC8220227

[95] Yang XR,Yu R.Correlation of exosomal microRNA clusters with bone metastasis in non-small cell lung cancer.Clin Exp Metastasis2021;38:109-17 PMCID:PMC7882559

[96] Wang Y,Dong B.Discovery of extracellular vesicles derived miR-181a-5p in patient’s serum as an indicator for bone-metastatic prostate cancer.Theranostics2021;11:878-92 PMCID:PMC7738844

[97] Bryant RJ,Catto JW.Changes in circulating microRNA levels associated with prostate cancer.Br J Cancer2012;106:768-74 PMCID:PMC3322952

[98] Biggs CN,Al-Zahrani AA.Prostate extracellular vesicles in patient plasma as a liquid biopsy platform for prostate cancer using nanoscale flow cytometry.Oncotarget2016;7:8839-49 PMCID:PMC4891008

[99] McKiernan J,Margolis E.A prospective adaptive utility trial to validate performance of a novel urine exosome gene expression assay to predict high-grade prostate cancer in patients with prostate-specific antigen 2-10ng/mL at initial biopsy.Eur Urol2018;74:731-8

[100] Barris DM,Dubin RA.Detection of circulating tumor DNA in patients with osteosarcoma.Oncotarget2018;9:12695-704 PMCID:PMC5849166

[101] Shulman DS,Imamovic-Tuco A.Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children’s oncology group.Br J Cancer2018;119:615-21 PMCID:PMC6162271

[102] Shukla NN,Magnan H.Plasma DNA-based molecular diagnosis, prognostication, and monitoring of patients with EWSR1 fusion-positive sarcomas.JCO Precis Oncol2017;2017:PO.16.00028 PMCID:PMC5881916

[103] Hayashi M,Meyer CF.Highly personalized detection of minimal Ewing sarcoma disease burden from plasma tumor DNA.Cancer2016;122:3015-23 PMCID:PMC5102400

[104] Zhang H,Xiao X.A liquid biopsy-based method for the detection and quantification of circulating tumor cells in surgical osteosarcoma patients.Int J Oncol2017;50:1075-86 PMCID:PMC5363882

[105] Li M,Long Z.Prognostic and clinicopathological significance of circulating tumor cells in osteosarcoma.J Bone Oncol2019;16:100236 PMCID:PMC6475710

[106] Wu ZJ,Qin X,Yuan ZC.Significance of circulating tumor cells in osteosarcoma patients treated by neoadjuvant chemotherapy and surgery.Cancer Manag Res2018;10:3333-9 PMCID:PMC6138968

[107] Chalopin A,Brown HK.Isolation of circulating tumor cells in a preclinical model of osteosarcoma: effect of chemotherapy.J Bone Oncol2018;12:83-90 PMCID:PMC6092555

[108] Benini S,Cocchi S.Detection of circulating tumor cells in liquid biopsy from Ewing sarcoma patients.Cancer Manag Res2018;10:49-60 PMCID:PMC5765973

[109] Schleiermacher G,Oberlin O.Increased risk of systemic relapses associated with bone marrow micrometastasis and circulating tumor cells in localized ewing tumor.J Clin Oncol2003;21:85-91

[110] Hayashi M,McCarty G.Size-based detection of sarcoma circulating tumor cells and cell clusters.Oncotarget2017;8:78965-77 PMCID:PMC5668012

[111] Bao Q,Wang J,Shen Y.Extracellular vesicle RNA sequencing reveals dramatic transcriptomic alterations between metastatic and primary osteosarcoma in a liquid biopsy approach.Ann Surg Oncol2018;25:2642-51

[112] Ma W,Chai J,Ren P.Circulating miR-148a is a significant diagnostic and prognostic biomarker for patients with osteosarcoma.Tumour Biol2014;35:12467-72

[113] Allen-rhoades W,Satterfield L.Cross-species identification of a plasma microRNA signature for detection, therapeutic monitoring, and prognosis in osteosarcoma.Cancer Med2015;4:977-88 PMCID:PMC4529336

[114] Wang SN,Liu C.miR-491 Inhibits Osteosarcoma Lung Metastasis and Chemoresistance by Targeting αB-crystallin.Mol Ther2017;25:2140-9 PMCID:PMC5589150

[115] Yang Z,Zhang X.Serum microRNA-221 functions as a potential diagnostic and prognostic marker for patients with osteosarcoma.Biomed Pharmacother2015;75:153-8

[116] Wang T,Dai Z,Yuan D.Increased expression of microRNA-191 as a potential serum biomarker for diagnosis and prognosis in human osteosarcoma.Cancer Biomark2015;15:543-50

[117] Zhou S,Hu J.miR-421 is a diagnostic and prognostic marker in patients with osteosarcoma.Tumour Biol2016;37:9001-7

[118] Cong C,Tian J,Zheng W.Identification of serum miR-124 as a biomarker for diagnosis and prognosis in osteosarcoma.Cancer Biomark2018;21:449-54

[119] Yao ZS,Liang D.Diagnostic and prognostic implications of serum miR-101 in osteosarcoma.Cancer Biomark2018;22:127-33 PMCID:PMC6004928

[120] Cai H,Tang J.Serum miR-195 is a diagnostic and prognostic marker for osteosarcoma.J Surg Res2015;194:505-10

[121] Nie CL,Ma Y,Han B.Circulating miR-125b as a biomarker of Ewing’s sarcoma in Chinese children.Genet Mol Res2015;14:19049-56

[122] Samuel G,Klein JB.Ewing sarcoma family of tumors-derived small extracellular vesicle proteomics identify potential clinical biomarkers.Oncotarget2020;11:2995-3012 PMCID:PMC7415402

[123] Russano M,Ribelli G.Liquid biopsy and tumor heterogeneity in metastatic solid tumors: the potentiality of blood samples.J Exp Clin Cancer Res2020;39:95 PMCID:PMC7254767

[124] Bettegowda C,Leary RJ.Detection of circulating tumor DNA in early- and late-stage human malignancies.Sci Transl Med2014;6:224ra24 PMCID:PMC4017867

[125] Schiavon G,Garcia-Murillas I.Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer.Sci Transl Med2015;7:313ra182 PMCID:PMC4998737

[126] O’Leary B,Morden JP.Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer.Nat Commun2018;9:896 PMCID:PMC5832789

[127] O’Leary B,Liu Y.The genetic landscape and clonal evolution of breast cancer resistance to palbociclib plus fulvestrant in the PALOMA-3 trial.Cancer Discov2018;8:1390-403 PMCID:PMC6368247

[128] Fribbens C,Kilburn L.Plasma ESR1 mutations and the treatment of estrogen receptor-positive advanced breast cancer.J Clin Oncol2016;34:2961-8

[129] Galardi F,Biagioni C.Circulating tumor cells and palbociclib treatment in patients with ER-positive, HER2-negative advanced breast cancer: results from a translational sub-study of the TREnd trial.Breast Cancer Res2021;23:38 PMCID:PMC7992319

[130] Okegawa T,Hara H,Nutahara K.Circulating tumor cells as a biomarker predictive of sensitivity to docetaxel chemotherapy in patients with castration-resistant prostate cancer.Anticancer Res2014;34:6705-10

[131] Liu W,Zhang YJ,Xue Y.MicroRNA-375 as a potential serum biomarker for the diagnosis, prognosis, and chemosensitivity prediction of osteosarcoma.J Int Med Res2018;46:975-83 PMCID:PMC5972241

[132] Yuan J,Chen X,Zhou X.Identification of serum microRNA-21 as a biomarker for chemosensitivity and prognosis in human osteosarcoma.J Int Med Res2012;40:2090-7

[133] Xavier CPR,Barbosa MAG,Guimarães JE.The role of extracellular vesicles in the hallmarks of cancer and drug resistance.Cells2020;9:1141 PMCID:PMC7290603

[134] Torreggiani E,Perut F,Baldini N.Multimodal transfer of MDR by exosomes in human osteosarcoma.Int J Oncol2016;49:189-96

[135] Yoshida A,Uotani K.Clinical and functional significance of intracellular and extracellular microRNA-25-3p in osteosarcoma.Acta Med Okayama2018;72:165-74

[136] Wei F,Zhou T.Exosomes derived from gemcitabine-resistant cells transfer malignant phenotypic traits via delivery of miRNA-222-3p.Mol Cancer2017;16:132 PMCID:PMC5526308

[137] Yuwen D,Wang D.Prognostic role of circulating exosomal miR-425-3p for the response of NSCLC to platinum-based chemotherapy.Cancer Epidemiol Biomarkers Prev2019;28:163-73

[138] Chen WX,Zhu B.Exosomal miR-222 from adriamycin-resistant MCF-7 breast cancer cells promote macrophages M2 polarization via PTEN/Akt to induce tumor progression.Aging (Albany NY)2021;13:10415-30 PMCID:PMC8064228

[139] Kreger BT,Cerione RA.The enrichment of survivin in exosomes from breast cancer cells treated with paclitaxel promotes cell survival and chemoresistance.Cancers (Basel)2016;8:111 PMCID:PMC5187509

[140] Ciravolo V,Ghedini GC.Potential role of HER2-overexpressing exosomes in countering trastuzumab-based therapy.J Cell Physiol2012;227:658-67

[141] Yang SJ,Li J.Predictive role of GSTP1-containing exosomes in chemotherapy-resistant breast cancer.Gene2017;623:5-14

[142] Wang T,Lu TX.Increasing circulating exosomes-carrying TRPC5 predicts chemoresistance in metastatic breast cancer patients.Cancer Sci2017;108:448-54 PMCID:PMC5378269

[143] Kharaziha P,Rutishauser D.Molecular profiling of prostate cancer derived exosomes may reveal a predictive signature for response to docetaxel.Oncotarget2015;6:21740-54 PMCID:PMC4673300

[144] Pittella-Silva F,Chan HT.Plasma or serum: which is preferable for mutation detection in liquid biopsy?.Clin Chem2020;66:946-57

[145] Merker JD,Compton C.Circulating tumor DNA Analysis in patients with cancer: american society of clinical oncology and college of american pathologists joint review.J Clin Oncol2018;36:1631-41

[146] Wong KHK,Miyamoto DT.Whole blood stabilization for the microfluidic isolation and molecular characterization of circulating tumor cells.Nat Commun2017;8:1733 PMCID:PMC5700979

[147] Fehm TN,Driemel C.Diagnostic leukapheresis for CTC analysis in breast cancer patients: CTC frequency, clinical experiences and recommendations for standardized reporting.Cytometry A2018;93:1213-9

[148] Terai M,Eschelman DJ.Arterial blood, rather than venous blood, is a better source for circulating melanoma cells.EBioMedicine2015;2:1821-6 PMCID:PMC4740300

[149] Buscail E,Laurent C.Tumor-proximal liquid biopsy to improve diagnostic and prognostic performances of circulating tumor cells.Mol Oncol2019;13:1811-26 PMCID:PMC6717761

[150] Heidrich I,Mossahebi Mohammadi P.Liquid biopsies: Potential and challenges.Int J Cancer2021;148:528-45

[151] Brennan K,FitzGerald SP.A comparison of methods for the isolation and separation of extracellular vesicles from protein and lipid particles in human serum.Sci Rep2020;10:1039 PMCID:PMC6978318

[152] Gancitano G,Dionisi M.Cost-consequence analysis of three different diagnostic strategies in the first- and second-line treatment of locally advanced or metastatic non-small-cell lung cancer.Health Econ Ther2018;19:1

[153] Siravegna G.Blood circulating tumor DNA for non-invasive genotyping of colon cancer patients.Mol Oncol2016;10:475-80 PMCID:PMC5528968

[154] Siravegna G.Genotyping cell-free tumor DNA in the blood to detect residual disease and drug resistance.Genome Biol2014;15:449 PMCID:PMC4281953

[155] Gutteridge A,Gibbons R.Digital PCR analysis of circulating tumor DNA: a biomarker for chondrosarcoma diagnosis, prognostication, and residual disease detection.Cancer Med2017;6:2194-202 PMCID:PMC5633548

[156] Catalano M.Inhibiting extracellular vesicles formation and release: a review of EV inhibitors.J Extracell Vesicles2020;9:1703244 PMCID:PMC6968539

[157] Hilton SH.Advances in the analysis of single extracellular vesicles: a critical review.Sens Actuators Rep2021;3:100052 PMCID:PMC8792802